Azathioprine vs methotrexate
Kidney function · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
197 questions · 203 findings · 17 reviews
No studies found 25 · 12.3%GRADE not reported 7 · 3.4%Very low 79 · 38.9%Low 49 · 24.1%Moderate 38 · 18.7%High 5 · 2.5%
Azathioprine vs methotrexate
Dialysis · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Azathioprine vs methotrexate
Relapse · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in relapse compared with methotrexate (low certainty).
1 finding from 1 review
- RR 1.1 [0.68, 1.77]1 study · 126 participantsLow
Azathioprine vs methotrexate
Adverse event causing death or study drug discontinuation · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in adverse events causing death or study drug discontinuation compared with methotrexate (low certainty).
1 finding from 1 review
- RR 0.58 [0.25, 1.38]1 study · 126 participantsLow
Azathioprine vs methotrexate
Severe adverse events · adults with renal vasculitis for maintenance therapy
Azathioprine may leads to lower severe adverse events compared with methotrexate (low certainty).
1 finding from 1 review
- RR 0.581 study · 126 participantsLow
Azathioprine vs no intervention
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether azathioprine changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
- Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes onlyOR 0.56 [0.32, 0.98]2 studies · 224 participantsVery low
Azathioprine vs no intervention
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Azathioprine vs no intervention
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Azathioprine vs no intervention
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Azathioprine vs cyclosporin of remission
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine (AZA) changes failure to maintain remission compared with cyclosporin of remission (very low certainty).
1 finding from 1 review
- Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes onlyRR 0.8 [0.33, 1.92]1 study · 16 participantsVery low
Azathioprine + infliximab vs infliximab
Clinical remission · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher clinical remission compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.26 [1.03, 1.54]1 study · 338 participantsModerate
Azathioprine + infliximab vs infliximab
Clinical remission off steroids · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher clinical remission off steroids compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.23 [1.02, 1.47]2 studies · 383 participantsModerate
Azathioprine + infliximab vs infliximab
Mucosal healing · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher mucosal healing compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.5 [1.02, 2.19]1 study · 210 participantsModerate
Azathioprine + infliximab vs infliximab
Adverse events · Patients with active Crohn's disease
Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.01 [0.94, 1.09]1 study · 342 participantsModerate
Azathioprine + infliximab vs infliximab
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.16 [0.75, 1.8]1 study · 342 participantsModerate
Azathioprine + infliximab vs infliximab
Serious adverse events · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 0.63 [0.41, 0.98]1 study · 342 participantsModerate
Azathioprine + infliximab vs infliximab
Maintenance of remission · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine and infliximab changes maintenance of remission compared with infliximab (very low certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes onlyRR 1.02 [0.74, 1.4]1 study · 36 participantsVery low
Azathioprine + infliximab vs infliximab
Adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine and infliximab changes adverse events compared with infliximab (very low certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes onlyRR 1.6 [0.33, 7.86]1 study · 45 participantsVery low
Azathioprine + infliximab vs infliximab
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine and infliximab changes withdrawals due to adverse events compared with infliximab (very low certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes onlyRR 2.42 [0.1, 56.46]1 study · 45 participantsVery low
Azathioprine + infliximab vs infliximab
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine and infliximab changes serious adverse events compared with infliximab (very low certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes onlyRR 2.42 [0.1, 56.46]1 study · 45 participantsVery low